Trial Profile

An Extension Study to Evaluate the Long-term Outcomes of Subjects Who Received Treatment for Retinopathy of Prematurity in Study 20090

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 05 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aflibercept (Primary)
Indications Retinopathy of prematurity
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms FIREFLEYE next
Sponsors Bayer

Most Recent Events

04 Apr 2024 Planned End Date changed from 3 Jul 2025 to 1 Oct 2025.
04 Apr 2024 Planned primary completion date changed from 3 Jul 2025 to 1 Oct 2025.
16 Jul 2023 This trial has been discontinued in Netherlands, according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com